Nature Communications

Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial

• David Hsiehchen
• John H. Lohrey
• Radhika Kainthla
• Syed Mohammad Ali Kazmi
• Nilesh Verma
• Carrie Manwaring
• Chul Ahn
• Hao Zhu

2026-07-21

Full text

DOI https://doi.org/10.1038/s41467-026-75554-z